Bullish
Telix Pharmaceuticals is gaining investor attention due to an upcoming critical FDA decision concerning its radiopharmaceutical pipeline, particularly...
Bullish
Telix Pharmaceuticals Limited announced that its marketing authorization application (MAA) for TLX101-Px (Pixlumi®), a glioma imaging candidate, has b...
Bullish
Telix Pharmaceuticals announced that its Marketing Authorization Application (MAA) for TLX101-Px (18F-FET), a brain cancer imaging candidate, has been...
Bullish
Telix Pharmaceuticals presented Phase 2 OPTIMAL-PSMA data for TLX597-Tx, a prostate cancer therapeutic, showing low uptake in salivary glands and kidn...